Virios Therapeutics, Inc. (VIRI)
After hours:
| Previous close | 6.56 |
| Open | 6.33 |
| Bid | 5.52 x 800 |
| Ask | 6.63 x 1000 |
| Day's range | 5.54 - 6.47 |
| 52-week range | 4.00 - 8.79 |
| Volume | |
| Avg. volume | 34,901 |
| Market cap | 50.399M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.38 |
| Earnings date | 12 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.33 |
- Business Wire
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference
ATLANTA, January 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.
- Business Wire
Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
ATLANTA, December 01, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that more than 50% of the patients planned for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1) study have been randomized.
- Business Wire
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
ATLANTA, November 11, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.
